Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, said that while there are a lot of quality measures being developed by several organizations, care gaps persist.
Although there are a lot of quality measures currently available, are there gaps that need to be filled? Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, said that while there are a lot of quality measures, with ASCO taking a lead in developing these, gaps persist. “Some of the quality measures are maybe too general to really differentiate high quality and low quality care,” Malin said, adding that measures might be too general to end up being meaningful.
There’s also the possibility of measure fatigue, especially in cancer, with its many subtypes, with specific treatments for each. What would be ideal, Malin said, would be the development of cross-cutting measures, such as Anthem’s approach for pathways adherence, which helps measure if the most appropriate treatment is being delivered. “The issue is coming up with a succinct number of measures that are really meaningful. It’s hard to do that with 200, but at the same time you need measures that don’t leave rare cancers, where arguably it’s the biggest challenge in making sure people get appropriate care, out of the picture,” Malin added.
Jason C. Goldwater, MA, MPA, senior director, National Quality Forum (NQF), agreed with Malin that care gaps do exist, and explained how NQF is working to explore these breaks and workout ways to fill them up. NQF, Goldwater said, facilitates and leads the Measure Application Partnership, which “brings together a lot of national experts in the area of oncology, again, from numerous sectors from payers to providers to consumers and so forth that talk about the measure gaps and talk about the measures that are needed.” The resulting recommendations are then turned in to the CMS with the hope of being commissioned.
Goldwater specifically discussed gaps in palliative and end-of-life care and also being able to understand disparities in cancer care, driven by socioeconomic and other factors. This, he believes, can help direct efforts in the right direction. “I think that we're still evolving that area and still working through to understand what we can best do to fill those gaps whether they come through a CMS sponsored project or whether they come from an organization's own initiative to determine whether or not that gap can be identified and filled and filled in such a way that it would create a sustainable metric that would be able to be used and evolved over time,” Goldwater added.
Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, is hopeful about Anthem’s efforts to provide patient outcomes data to the individual physician or clinic—whether they visited the emergency room or the hospital, the frequency of the visits, etc. this information, Bosserman said, is usually not available in real-time to the clinic, unless they have a system in place that queries the patient on it. “It's really going to take this larger partnership, partnership between the primary doctors. How are we looking at overall health outcomes at the primary care levels…the hospital, the emergency room, and then how do we tie in hospice and palliative care in more effective ways. There are a lot of gaps and huge opportunities,” Bosserman said. These conversations between providers and payers can push us toward solutions, she said.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More